Literature DB >> 23331132

C-reactive protein, immunoglobulin G and complement co-localize in renal immune deposits of proliferative lupus nephritis.

Christopher Sjöwall1, Anders I Olin, Thomas Skogh, Jonas Wetterö, Matthias Mörgelin, Ola Nived, Gunnar Sturfelt, Anders A Bengtsson.   

Abstract

The pattern recognition molecules C-reactive protein (CRP) and C1q are of big interest in relation to the pathogenesis of systemic lupus erythematosus (SLE). Circulating autoantibodies against CRP and C1q are frequently found in SLE patients with active disease, particularly in lupus nephritis (LN), and rising levels reportedly relate to disease activity and outcome. If CRP-, or dsDNA- and/or C1q-containing immune complexes (ICs) are pathogenic in LN, glomerular IgG-deposits would be expected to co-localize with these antigens. In search for proof of this concept, renal biospsies from patients with active LN (n = 5) were examined with high-resolution immunogold electron microscopy. Renal biopsies from patients with Henoch-Schönlein purpura, pauci-immune nephritis and renal cancer served as controls. IgG antibodies against CRP, C1q and nucleosomes were analyzed in pre-post flare sera. We could demonstrate that CRP, C1q, C3c and dsDNA were co-localized with IgG in electron dense deposits in the glomerular basement membrane/subendothelial space in all of the 5 LN patients. Deposits of IgG, CRP, complement and dsDNA were 10-fold higher in LN compared to controls. All SLE patients had circulating anti-nucleosome antibodies; 4/5 had serum antibodies against CRP, dsDNA, and C1q at biopsy/flare. Despite a limited number of cases, the results support the notion of a pathogenic role not only for anti-dsDNA antibodies, but also for anti-CRP and anti-C1q in LN. The glomerular ICs may have been generated by deposition of circulating ICs or by in situ IC formation.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23331132     DOI: 10.3109/08916934.2013.764992

Source DB:  PubMed          Journal:  Autoimmunity        ISSN: 0891-6934            Impact factor:   2.815


  12 in total

1.  Altered glycan accessibility on native immunoglobulin G complexes in early rheumatoid arthritis and its changes during therapy.

Authors:  J Stümer; M H C Biermann; J Knopf; I Magorivska; A Kastbom; A Svärd; C Janko; R Bilyy; G Schett; C Sjöwall; M Herrmann; L E Muñoz
Journal:  Clin Exp Immunol       Date:  2017-06-13       Impact factor: 4.330

Review 2.  Evasion and interactions of the humoral innate immune response in pathogen invasion, autoimmune disease, and cancer.

Authors:  Trisha A Rettig; Julie N Harbin; Adelaide Harrington; Leonie Dohmen; Sherry D Fleming
Journal:  Clin Immunol       Date:  2015-07-02       Impact factor: 3.969

3.  Altered frequencies of memory B cells in new-onset systemic lupus erythematosus patients.

Authors:  Li Zhu; Zijing Yin; Bomiao Ju; Jing Zhang; Yanhua Wang; Xiaohong Lv; Zhiming Hao; Lan He
Journal:  Clin Rheumatol       Date:  2017-10-25       Impact factor: 2.980

4.  Interferon-α coincides with suppressed levels of pentraxin-3 (PTX3) in systemic lupus erythematosus and regulates leucocyte PTX3 in vitro.

Authors:  L Wirestam; H Enocsson; T Skogh; M L Eloranta; L Rönnblom; C Sjöwall; J Wetterö
Journal:  Clin Exp Immunol       Date:  2017-03-31       Impact factor: 4.330

5.  Associations of C-reactive protein isoforms with systemic lupus erythematosus phenotypes and disease activity.

Authors:  Jesper Karlsson; Jonas Wetterö; Maria Weiner; Johan Rönnelid; Rafael Fernandez-Botran; Christopher Sjöwall
Journal:  Arthritis Res Ther       Date:  2022-06-11       Impact factor: 5.606

6.  Osteopontin is associated with disease severity and antiphospholipid syndrome in well characterised Swedish cases of SLE.

Authors:  Lina Wirestam; Martina Frodlund; Helena Enocsson; Thomas Skogh; Jonas Wetterö; Christopher Sjöwall
Journal:  Lupus Sci Med       Date:  2017-07-28

7.  Pronounced Diurnal Pattern of Salivary C-Reactive Protein (CRP) With Modest Associations to Circulating CRP Levels.

Authors:  Jonas Wetterö; Sarah von Löhneysen; Flordelyn Cobar; Margareta Kristenson; Peter Garvin; Christopher Sjöwall
Journal:  Front Immunol       Date:  2021-01-08       Impact factor: 7.561

8.  Prognostic value of anti-CRP antibodies in lupus nephritis in long-term follow-up.

Authors:  Satu Sinikka Pesickova; Romana Rysava; Martin Lenicek; Libor Vitek; Eliska Potlukova; Zdenka Hruskova; Eva Jancova; Eva Honsova; Jakub Zavada; Marten Trendelenburg; Vladimir Tesar
Journal:  Arthritis Res Ther       Date:  2015-12-24       Impact factor: 5.156

9.  Two-Parametric Immunological Score Development for Assessing Renal Involvement and Disease Activity in Systemic Lupus Erythematosus.

Authors:  Christopher Sjöwall; Chelsea Bentow; Mary Ann Aure; Michael Mahler
Journal:  J Immunol Res       Date:  2018-08-30       Impact factor: 4.818

10.  Increased levels of anti-dsDNA antibodies in immune complexes before treatment with belimumab associate with clinical response in patients with systemic lupus erythematosus.

Authors:  Azita Sohrabian; Ioannis Parodis; Nellie Carlströmer-Berthén; Martina Frodlund; Andreas Jönsen; Agneta Zickert; Christopher Sjöwall; Anders A Bengtsson; Iva Gunnarsson; Johan Rönnelid
Journal:  Arthritis Res Ther       Date:  2019-11-29       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.